Abstract Search

The evidence base for starting early insulin treatment in patients with type 2 diabetes is rather scanty. In the UKPDS trial the intensive treatment of hyperglycaemia in newly detected patients with type 2 diabetes based on insulin or sulponylurea (no separation possible) revealed a significant reduction of myocardial infarction risk (15%, P=0.01), but only after prolonged post-study follow-up after 10 years1. In 2012 the ORIGIN study was published showing ...

0 shares

ea0070oc3.3 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Circulating follistatin predicts type 2 diabetes risk

Wu Chuanyan , Borné Yan , Gao Rui , López Rodriguez Maykel , Roell William , Wilson Jonathan , Ahlqvist Emma , Luan Cheng , Peter Andreas , Machann Jürgen , Hong Mun-Gwan , Schwenk Jochen , Nilsson Peter , Shore Angela , Khan Faisel , Natali Andrea , Melander Olle , Orho-Melander Marju , Nilsson Jan , Renström Erik , Wollheim Claes , Pearson Ewan , Franks Paul , White Morris , Duffin Kevin , Vaag Allan , Laakso Markku , Stefan Norbert , Groop Leif , De Marinis Yang

Follistatin is a hepatokine found to be elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. We report that elevated baseline circulating follistatin levels predict future T2D incidence in longitudinal cohorts including up to 5274 individuals. Individuals with elevated circulating follistatin had higher risk of developing type 2 diabetes during follow-up of 4 years (IMI-DIRECT-METSIM, n = 1079, Finland), 5 and 19 years (MDC-CC, n...

0 shares

Endocrine Abstracts

Early insulin treatment in type 2 diabetes

Circulating follistatin predicts type 2 diabetes risk

BiosciAbstracts